Rock Springs Capital Management LP Cyma Bay Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $1.2 Million - $5.34 Million	-900,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $1.12 Million - $2.53 Million	185,000 Added 25.87%	900,000 $6.44 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $827,391 - $1.36 Million	101,396 Added 16.52%	715,000 $9.5 Million
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $365,611 - $487,930	33,604 Added 5.79%	613,604 $6.8 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $959,400 - $1.29 Million	90,000 Added 18.37%	580,000 $7.78 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $360,000 - $606,400	40,000 Added 8.89%	490,000 $6.37 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $2.68 Million - $3.72 Million	450,000	450,000 $3.63 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.